Another interesting observation in our cohort is that breast cancers with PTEN mutations were more likely to be HER2-negative, while no significant differences between patients with/without PTEN mutations in terms of age, ER status, PR status, tumor size, lymph node metastasis, and Ki67 score. This evidence concerns the gene PTEN and metastatic malignant neoplasm in the lymph nodes.